Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teplizumab in newly diagnosed type 1 diabetes
NCT03875729Phase 3Completed
- Sponsor
- Provention Bio
- Start
- Apr 2019
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of teplizumab in type 1 diabetes mellitus (T1D), sponsored by Provention Bio. Started Apr 2019; status: completed.
02
Drugs
teplizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03875729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03875729.